Online inquiry

IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11824MR)

This product GTTS-WQ11824MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11824MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5272MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ14446MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ13579MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ7176MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ5438MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ14037MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ2030MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ6682MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DMUC5754A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW